Successful second allogeneic stem cell transplantation in second remission induced by dasatinib in a child with Philadelphia chromosome positive acute lymphoblastic leukemia

Pediatric Blood and Cancer

Volumn 52, Issue 7, 2009, Pages 891-892

  Millot, Frédéric ^a   Cividin, Marie ^a   Brizard, Françoise ^a   Chomel, Jean Claude ^a   Méchinaud, Françoise ^b   Guilhot, François ^a  

^a POITIERS UNIVERSITY HOSPITAL   (France)

^b NANTES UNIVERSITY HOSPITAL   (France)

Author keywords

Acute lymphoblastic leukemia; Dasatinib; Philadelphia chromosome; Tyrosine kinase inhibitors

Indexed keywords

ASPARAGINASE; BCR ABL PROTEIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYCLOSPORIN A; DASATINIB; DAUNORUBICIN; DEXAMETHASONE; FLUDARABINE; IMATINIB; MESSENGER RNA; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID; VINCRISTINE;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BONE MARROW BIOPSY; BONE PAIN; CASE REPORT; CHILD; CYTOGENETICS; DRUG TOLERABILITY; FOLLOW UP; GRAFT VERSUS HOST REACTION; HLA MATCHING; HUMAN; IMMUNOPHENOTYPING; KARYOTYPE 46,XY; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LEUKOCYTE COUNT; LYMPHOBLASTOID CELL; MALE; MULTIPLE CYCLE TREATMENT; MYELOABLATIVE CONDITIONING; NEUTROPENIA; PHILADELPHIA CHROMOSOME POSITIVE CELL; PRESCHOOL CHILD; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THROMBOCYTOPENIA; WHOLE BODY RADIATION;

CHILD, PRESCHOOL; FUSION PROTEINS, BCR-ABL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PHILADELPHIA CHROMOSOME; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTEIN KINASE INHIBITORS; PYRIMIDINES; REMISSION INDUCTION; SALVAGE THERAPY; THIAZOLES; TRANSPLANTATION, HOMOLOGOUS;

EID: 67650478307     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.21938     Document Type: Article

References (11)

1. Garcia-Manero G, Thomas DA. Salvage therapy for refractory or relapsed acute lymphocytic leukemia. Hematol Oncol Clin North Am 2001;15:163-205. (Pubitemid 32201872)
2. Ottman O, Dombret H, Martinelli G, et al. Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia with resistance or intolerance to imatinib: Interim results of a phase 2 study. Blood 2007;110:2309-2315. (Pubitemid 47523149)
3. Zwaan CM, Den Boer ML, Beverloo HB, et al. Dasatinib in children and adolescents with relapsed or refractory leukemia: Preliminary results of the CA 180018 phase I/II study from the ITCC consortium. Blood 2007;110: Abstract # 1049.
4. Kolb EA, Gorlik R, Houghton PJ, et al. Initial testing of dasatinib by the pediatric preclinical testing program. Pediatr Blood Cancer 2008;50:1198-1206. (Pubitemid 351555544)
5. Moricke A, Reiter A, Zimmermann M, et al. Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: Treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood 2008;111:4477-4489.
6. De Labarthe A, Rousselot P, Huguet-Rigal F, et al. Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: Results of the GRAAPH-2003 study. Blood 2007;109:1408-1413. (Pubitemid 46239571)
7. Yanada M, Sugiura I, Takeuchi J, et al. Prospective monitoring of BCR-ABL 1 transcript levels in patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia undergoing imatinibcombined chemotherapy. Br J Haematol 2008;143:503-510.
8. Schultz KR, Bowman WP, Layton W, et al. Improved early event free survival in children with Philadelphia chromosome positive acute lymphoblastic leukaemia with intensive imatinib in combination with high dose chemotherapy: Children's Oncology Group study AALL0031. Blood 2007;110: Abstract # 776.
9. Lombardo LJ, Lee FY, Chen P, et al. Discovery of N-(2 chloro- 6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin- 4ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 2004;47:6658-6661. (Pubitemid 40053752)
10. Keam SJ. Dasatinib in chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. Biodrugs 2008;22:59-69. (Pubitemid 351158536)
11. Porkka K, Koskenvesa P, Lundan T, et al. Dasatinib crosses the brain-blood barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia. Blood 2008; 112:1002-1005.